KyriakosPeterPapadopoulosMD

Oncology • San Antonio, TX

Senior Clinical Investigator at START in San Antonio

Join to view full profile

Are you Dr. Papadopoulos?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 65 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
4383 Medical Dr
San Antonio, TX 78229
Phone+1 210-593-5700

Fax+1 210-593-5992

Summary

Dr. Kyriakos Papadopoulos, MD is an oncologist in San Antonio, Texas. He is currently licensed to practice medicine in Texas and New York. He is affiliated with Methodist Hospital and Northeast Baptist Hospital.

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 1999
New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematology and Medical Oncology, 1994 - 1997
University of the WitwatersrandClass of 1985

Certifications & Licensure

TX State Medical License 2004 - 2025
NY State Medical License 1997 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:SE Texas Castle Connolly, 2013

Clinical Trials

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2001 Apr 01
Terminated
Phase 1
Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma Start of enrollment: 2001 Oct 01
Unknown status
Phase 1
Study of NMS-1116354 in Solid Tumors Start of enrollment: 2009 Apr 01
Terminated
Phase 1
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2010 Oct 01
Completed
Phase 1, Phase 2
A Study of DS-2248 in Participants With Advanced Solid Tumors Start of enrollment: 2011 Mar 29
Terminated
Phase 1
Study of PM060184 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
Completed
Phase 1
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
Active, not recruiting
Phase 1
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) Start of enrollment: 2016 Feb 01
Recruiting
Phase 1
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression Start of enrollment: 2017 May 18
Terminated
Phase 1
A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Start of enrollment: 2017 Sep 12
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F Garrido
Clinical Cancer Research. 2024-12-16
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16
2 citations
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.
Rona Yaeger, Meredith A McKean, Rizwan Haq, J Thaddeus Beck, Matthew H Taylor
Cancer Discovery. 2024-09-04

Press Mentions

START & Sarah Cannon Partner to Advance Therapies for Patients with CancerJanuary 16th, 2018
FDA Grants Cemiplimab Breakthrough Designation for CSCCSeptember 8th, 2017
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual MeetingJune 4th, 2017
Join now to see all